Insulet Corporation (NASDAQ:PODD) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Insulet Corporation has received a consensus recommendation of "Moderate Buy" from eighteen brokerages, with sixteen analysts giving a buy rating and an average 1-year target price of $332.70.
• The company reported a strong earnings performance, with an EPS of $1.17 for the recent quarter, exceeding the consensus estimate, and revenue growth of 32.9% compared to the same period last year.
• Several institutional investors have increased their positions in Insulet, including State of Wyoming, which raised its holdings by 91.5% in the second quarter.

Shares of Insulet Corporation (NASDAQ:PODD - Get Free Report) have received an average recommendation of "Moderate Buy" from the eighteen research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $332.7059.

PODD has been the topic of several analyst reports. Wells Fargo & Company lifted their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Oppenheimer lifted their price target on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Citigroup reiterated a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th.

Insulet Stock Performance

PODD stock traded up $3.25 on Tuesday, hitting $337.60. The company had a trading volume of 457,992 shares, compared to its average volume of 714,523. Insulet has a 12-month low of $199.68 and a 12-month high of $337.84. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock's 50-day simple moving average is $303.31 and its 200 day simple moving average is $287.23. The stock has a market cap of $23.76 billion, a price-to-earnings ratio of 102.61, a P/E/G ratio of 2.80 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same quarter last year, the company posted $0.55 earnings per share. The firm's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts expect that Insulet will post 3.92 earnings per share for the current fiscal year.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently modified their holdings of PODD. Larson Financial Group LLC raised its position in shares of Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 81 shares during the period. Zions Bancorporation National Association UT bought a new stake in shares of Insulet during the 1st quarter valued at $26,000. SouthState Corp raised its position in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 76 shares during the period. Kozak & Associates Inc. bought a new stake in shares of Insulet during the 2nd quarter valued at $32,000. Finally, Golden State Wealth Management LLC raised its position in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock valued at $32,000 after purchasing an additional 69 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.